{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T22:43:29Z","timestamp":1784414609784,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00270-022-03254-4","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T20:02:31Z","timestamp":1661457751000},"page":"1725-1734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90)"],"prefix":"10.1007","volume":"45","author":[{"given":"Richard","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Thirunavu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Bercu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ila","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neela","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Switchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Weakland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4569-2720","authenticated-orcid":false,"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"issue":"1","key":"3254_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends\u2014an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16\u201327. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0578.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"3254_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4251\/wjgo.v12.i2.228","volume":"12","author":"M Feretis","year":"2020","unstructured":"Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: a systematic review. World J Gastrointest Oncol. 2020;12(2):228\u201336. https:\/\/doi.org\/10.4251\/wjgo.v12.i2.228.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"3254_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"3254_CR4","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/cncr.21778","volume":"106","author":"KR Hess","year":"2006","unstructured":"Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624\u201333. https:\/\/doi.org\/10.1002\/cncr.21778.","journal-title":"Cancer"},{"key":"3254_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12967-015-0425-0","volume":"13","author":"R Ma","year":"2015","unstructured":"Ma R, Feng Y, Lin S, et al. Mechanisms involved in breast cancer liver metastasis. J Transl Med. 2015;13:64. https:\/\/doi.org\/10.1186\/s12967-015-0425-0.","journal-title":"J Transl Med"},{"key":"3254_CR6","doi-asserted-by":"publisher","unstructured":"Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol Off J Eur Soc Med Oncol. 2003;14 Suppl 2:ii13\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdg731","DOI":"10.1093\/annonc\/mdg731"},{"issue":"4","key":"3254_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1245\/s10434-013-3436-1","volume":"21","author":"A Saxena","year":"2014","unstructured":"Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol. 2014;21(4):1296\u2013303. https:\/\/doi.org\/10.1245\/s10434-013-3436-1.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"3254_CR8","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.21037\/tcr-20-1598","volume":"9","author":"K Terata","year":"2020","unstructured":"Terata K, Imai K, Wakita A, Sato Y, Motoyama S, Minamiya Y. Surgical therapy for breast cancer liver metastases. Transl Cancer Res. 2020;9(8):5053\u201362. https:\/\/doi.org\/10.21037\/tcr-20-1598.","journal-title":"Transl Cancer Res"},{"key":"3254_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jss.2020.09.022","volume":"259","author":"JCA Millen","year":"2021","unstructured":"Millen JCA, Hofmann A, Mesquita-Neto JW, Rose J, Macedo FI. Evolving role of liver resection in selected patients with metastatic breast cancer. J Surg Res. 2021;259:363\u201371. https:\/\/doi.org\/10.1016\/j.jss.2020.09.022.","journal-title":"J Surg Res"},{"issue":"10","key":"3254_CR10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jvir.2014.07.007","volume":"25","author":"AC Gordon","year":"2014","unstructured":"Gordon AC, Gradishar WJ, Kaklamani VG, et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014;25(10):1523-1532.e2. https:\/\/doi.org\/10.1016\/j.jvir.2014.07.007.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3254_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100838","volume":"7","author":"E Barakat","year":"2022","unstructured":"Barakat E, Bibok A, Rishi A, et al. Transarterial Yttrium-90 glass microsphere radioembolization of chemotherapy-refractory breast cancer liver metastases: results of a single institution retrospective study. Adv Radiat Oncol. 2022;7(1): 100838. https:\/\/doi.org\/10.1016\/j.adro.2021.100838.","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"3254_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.tvir.2019.02.008","volume":"22","author":"SA Padia","year":"2019","unstructured":"Padia SA. Y90 clinical data update: cholangiocarcinoma, neuroendocrine tumor, melanoma, and breast cancer metastatic disease. Tech Vasc Interv Radiol. 2019;22(2):81\u20136. https:\/\/doi.org\/10.1053\/j.tvir.2019.02.008.","journal-title":"Tech Vasc Interv Radiol"},{"issue":"9","key":"3254_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jvir.2016.05.028","volume":"27","author":"CC Pieper","year":"2016","unstructured":"Pieper CC, Meyer C, Wilhelm KE, et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases\u2014a single-center experience. J Vasc Interv Radiol. 2016;27(9):1305\u201315. https:\/\/doi.org\/10.1016\/j.jvir.2016.05.028.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3254_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jvir.2011.09.028","volume":"23","author":"L Bester","year":"2012","unstructured":"Bester L, Meteling B, Pocock N, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2012;23(1):96\u2013105. https:\/\/doi.org\/10.1016\/j.jvir.2011.09.028.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"3254_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jvir.2019.12.013","volume":"31","author":"NA Davisson","year":"2020","unstructured":"Davisson NA, Bercu ZL, Friend SC, et al. Predictors of survival after Yttrium-90 radioembolization of chemotherapy-refractory hepatic metastases from breast cancer. J Vasc Interv Radiol. 2020;31(6):925\u201333. https:\/\/doi.org\/10.1016\/j.jvir.2019.12.013.","journal-title":"J Vasc Interv Radiol"},{"issue":"15","key":"3254_CR16","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3390\/cancers13153777","volume":"13","author":"I Schatka","year":"2021","unstructured":"Schatka I, Tschernig M, Rogasch JMM, et al. Selective internal radiation therapy in breast cancer liver metastases: outcome assessment applying a prognostic score. Cancers (Basel). 2021;13(15):3777. https:\/\/doi.org\/10.3390\/cancers13153777.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3254_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00330-012-2556-5","volume":"23","author":"R Cianni","year":"2013","unstructured":"Cianni R, Pelle G, Notarianni E, et al. Radioembolisation with 90Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol. 2013;23(1):182\u20139. https:\/\/doi.org\/10.1007\/s00330-012-2556-5.","journal-title":"Eur Radiol"},{"issue":"3","key":"3254_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00259-015-3157-8","volume":"43","author":"E Garin","year":"2016","unstructured":"Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT\/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43(3):559\u201375. https:\/\/doi.org\/10.1007\/s00259-015-3157-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3254_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jvir.2010.10.029","volume":"22","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Gates VL, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22(3):265\u201378. https:\/\/doi.org\/10.1016\/j.jvir.2010.10.029.","journal-title":"J Vasc Interv Radiol"},{"key":"3254_CR20","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0168-8278(18)30243-5","volume":"68","author":"A-L Hermann","year":"2018","unstructured":"Hermann A-L, Dieudonn\u00e9 A, Maxime R, et al. Role of 99mTc-macroaggregated albumin SPECT\/CT based dosimetry in predicting survival and tumor response of patients with locally advanced and inoperable hepatocellular carcinoma (HCC) treated by selective intra-arterial radiation therapy (SIRT) with yttr. J Hepatol. 2018;68:S13. https:\/\/doi.org\/10.1016\/S0168-8278(18)30243-5.","journal-title":"J Hepatol"},{"issue":"2","key":"3254_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jvir.2013.11.007","volume":"25","author":"N Kokabi","year":"2014","unstructured":"Kokabi N, Galt JR, Xing M, et al. A simple method for estimating dose delivered to hepatocellular carcinoma after Yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. J Vasc Interv Radiol. 2014;25(2):277\u201387. https:\/\/doi.org\/10.1016\/j.jvir.2013.11.007.","journal-title":"J Vasc Interv Radiol"},{"key":"3254_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3254_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"O Jh","year":"2016","unstructured":"Jh O, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043.","journal-title":"Radiology"},{"issue":"10","key":"3254_CR24","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jvir.2008.07.009","volume":"19","author":"JE Stuart","year":"2008","unstructured":"Stuart JE, Tan B, Myerson RJ, et al. Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol. 2008;19(10):1427\u201333. https:\/\/doi.org\/10.1016\/j.jvir.2008.07.009.","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"3254_CR25","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1200\/JCO.1994.12.8.1639","volume":"12","author":"K Porkka","year":"1994","unstructured":"Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrh\u00f6nen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol. 1994;12(8):1639\u201347. https:\/\/doi.org\/10.1200\/JCO.1994.12.8.1639.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3254_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.1987.5.5.773","volume":"5","author":"JW Zinser","year":"1987","unstructured":"Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987;5(5):773\u201382. https:\/\/doi.org\/10.1200\/JCO.1987.5.5.773.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3254_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.115.165050","volume":"57","author":"WP Fendler","year":"2016","unstructured":"Fendler WP, Lechner H, Todica A, et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single-center experience in 81 patients. J Nucl Med. 2016;57(4):517\u201323. https:\/\/doi.org\/10.2967\/jnumed.115.165050.","journal-title":"J Nucl Med"},{"issue":"9","key":"3254_CR28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.jvir.2016.06.016","volume":"27","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for breast cancer liver metastases. J Vasc Interv Radiol. 2016;27(9):1316\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2016.06.016.","journal-title":"J Vasc Interv Radiol"},{"key":"3254_CR29","unstructured":"Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 1996;6(2):474\u2013480. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12056099"},{"issue":"5","key":"3254_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1055\/s-0040-1720954","volume":"37","author":"A Villalobos","year":"2020","unstructured":"Villalobos A, Soliman MM, Majdalany BS, et al. Yttrium-90 radioembolization dosimetry: what trainees need to know. Semin Interv Radiol. 2020;37(5):543\u201354. https:\/\/doi.org\/10.1055\/s-0040-1720954.","journal-title":"Semin Interv Radiol"},{"issue":"8","key":"3254_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/BF01084369","volume":"23","author":"S Ho","year":"1996","unstructured":"Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23(8):947\u201352. https:\/\/doi.org\/10.1007\/BF01084369.","journal-title":"Eur J Nucl Med"},{"issue":"5","key":"3254_CR32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain H, Bagni O, Deroose CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570\u201384. https:\/\/doi.org\/10.1007\/s00259-020-05163-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"3254_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MNM.0000000000001345","volume":"42","author":"B Cheng","year":"2021","unstructured":"Cheng B, Sethi I, Davisson N, et al. Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. Nucl Med Commun. 2021;42(4):402\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001345.","journal-title":"Nucl Med Commun"},{"key":"3254_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109539","volume":"136","author":"F Ridouani","year":"2021","unstructured":"Ridouani F, Soliman MM, England RW, et al. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer. Eur J Radiol. 2021;136: 109539. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109539.","journal-title":"Eur J Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-022-03254-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T17:13:37Z","timestamp":1667322817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-022-03254-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3254"],"URL":"https:\/\/doi.org\/10.1007\/s00270-022-03254-4","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nima Kokabi is a consultant and proctor for Sirtex Medical. He also conducts other ongoing research supported by Sirtex Medical. Kevin Kalinsky reports grants\/contracts to his institution from Incyte, Novartis, Genentch, Eli-Lilly, Pfizer, Calithera, Immunomedics, Acetylon, Seattle Genetics, Amgen, Zentalis, and CytomX Therapeutics;\u00a0consulting fees\/consultant honorarium from Daiichi Sankyo, Eli-Lilly, Pfizer, Novartis, Eisai, AstraZeneca, Immunomedics, Merck, Seattle Genetics, Cyclocel, Oncosec, and 4D Pharma; speakers bureau: Eli-Lilly; support for attending meetings and\/or travel from Eli-Lilly, AstraZeneca, Pfizer; participation on advisory board (steering committee): Immunomedics, AstraZeneca, Ambryx, Genentech; and stock options\/employment: Grail (spouse), Array BioPharma (spouse), and Pfizer (spouse).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval of this study was provided by the institutional review board, IRB, of Emory University and the respective institutional IRB at each subsite. Additionally, investigational device exemption, IDE, was obtained from United States\u2019 Food and Drug Administration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For this type of study, consent for publication is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Informed consent will be obtained from all individual participants included in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}